Daiichi Sankyo Q2 FY2027: Sales and profit rise as forecast holds

Daiichi Sankyo reported year-on-year growth in revenue, operating profit and profit attributable to owners of the parent for the six months ended September 2026. Revenue rose 19.7%, operating profit increased 34.4% and interim profit attributable to owners of the parent climbed 15.8%.

• Core operating profit: Rose 46.9% to ¥221.3 billion, helped by higher revenue and the weaker yen
• Interim profit before tax: Increased 18.2% to ¥192.8 billion. Higher financial expenses, among other factors, tempered the gain in operating profit
• Basic earnings per share: Rose to ¥83.22 from ¥70.55 a year earlier
• Gap between operating profit and core operating profit: Business restructuring expenses and other items were recorded outside core operating profit, leaving operating profit growth below the increase in core operating profit

Growth in cancer drugs including Enhertu and Datroway, along with the weaker yen, drove revenue higher. Selling, general and administrative expenses also increased, including costs related to co-development with AstraZeneca. Research and development spending rose as Daiichi Sankyo expanded investment in five DXd antibody-drug conjugates and its next-generation product portfolio, Next Wave. Revenue momentum supported earnings, but cost trends, including development investment and restructuring expenses, will be important to margins ahead.

Daiichi Sankyo operates as a single pharmaceutical segment and does not disclose results by reportable segment in its earnings release. The excerpt available here also does not include readable figures for regional revenue, so this section focuses on product trends and the factors the company cited.

Key cancer drugs including Enhertu and Datroway gained traction and contributed to companywide revenue growth. Foreign exchange also boosted sales, although some products and regions weighed on revenue, so growth was not uniform across all markets.

• Enhertu: Won approvals in the U.S., Europe, China and other markets across multiple lines of treatment and cancer types, including breast cancer. Expanded indications are widening its sales opportunities
• Datroway: Won approvals for uses including first-line breast cancer treatment in the U.S. and Europe, and also gained approval in Japan. Clinical development and expansion into additional markets progressed
• Differences by region and product: Growth in key drugs was partly offset by revenue declines for some products. Foreign-exchange translation also provided a boost

Daiichi Sankyo's growth depends not only on expanding sales of its leading drugs but also on extending their indications and geographic reach through new approvals. Because the company reports a single segment, comparisons of profitability between businesses are not available. The spread of products such as Enhertu across regions and lines of treatment will be a key driver of future growth.

Total assets increased from the end of the previous fiscal year, while the ratio of equity attributable to owners of the parent declined. Daiichi Sankyo expects to pay an annual dividend of ¥100 per share, up ¥22 from the previous fiscal year.

The company said total assets rose from the previous year-end, reflecting increases in cash and cash equivalents, inventories and property, plant and equipment, among other factors. A cash flow statement was also disclosed, but the excerpt available here does not show legible figures for individual activities. Daiichi Sankyo's basic policy is to maintain or increase dividends over time, balancing growth investment with shareholder returns. It also views share repurchases as an option in its capital policy.

Daiichi Sankyo left its FY2027 full-year forecast unchanged from its previous announcement. Despite first-half growth in both revenue and profit, the company maintained its outlook for revenue of ¥2.34 trillion and operating profit of ¥320 billion.

First-half revenue represented about 49.9% of the full-year forecast, while operating profit reached about 60.6%. Growth in key drugs and the weaker yen supported progress, but the company expects full-year profit attributable to owners of the parent to decline from the previous year. The earnings release did not detail why the forecast was maintained. Sales trends in the second half, development and restructuring costs, and foreign-exchange movements will be key to assessing whether Daiichi Sankyo meets its targets.

Daiichi Sankyo is investing to enhance the value of its five DXd antibody-drug conjugates and to develop its next wave of growth products. Research and development spending increased year on year, as the company pursued expanded indications for leading drugs alongside the development of next-generation drug-discovery capabilities.

• DXd ADCs: Concentrating resources on five products, including trastuzumab deruxtecan (Enhertu), and accelerating clinical development
• Expanded indications: Enhertu has won approvals for uses including breast cancer and solid tumors. Datroway has also advanced in breast cancer treatment in the U.S., Europe and Japan, among other markets
• Next Wave: Advancing global clinical development to create a portfolio of products that could change standards of care
• Technology platform: Deepening ADC technology while broadening research into multiple non-ADC modalities, with a goal of identifying multiple BGTs to follow DXd ADCs by fiscal 2030

Higher R&D spending weighs on near-term profit, but approvals and expanded indications can open up additional sales opportunities. For investors, a key measure over the medium to long term will be whether existing leading products sustain growth and whether candidates in development can become the next pillars of revenue.

Expanded sales of leading drugs and additional indications are supporting growth, but pharmaceutical development carries uncertainty around clinical trials and regulatory approvals. The following areas warrant attention in light of the business environment and development updates cited by the company.

• Foreign-exchange movements: Yen weakness boosted revenue and profit on translation, but a reversal could weigh on results
• Reliance on key products: Growth in drugs such as Enhertu is underpinning performance, leaving companywide results exposed to shifts in sales trends and competition
• Clinical development and approvals: Trial results and regulatory reviews could affect the timing of launches or expanded indications, as well as sales opportunities
• Uncertainty around development candidates: Daiichi Sankyo voluntarily withdrew its U.S. application for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer. The effects on development plans and expected revenue need to be assessed
• Rising costs: R&D spending and selling expenses related to co-development have increased. The challenge is converting revenue growth into profit growth

Daiichi Sankyo is pursuing expanded indications for its leading products while investing in next-generation candidates. Investors will need to track not only sales growth but also clinical trial results, regulatory approvals and whether investment costs are recovered as planned.